Allele-Specific CRISPR/Cas9 Correction of a Heterozygous DNM2 Mutation Rescues Centronuclear Myopathy Cell Phenotypes

Genome editing with the CRISPR/Cas9 technology has emerged recently as a potential strategy for therapy in genetic diseases. For dominant mutations linked to gain-of-function effects, allele-specific correction may be the most suitable approach. In this study, we tested allele-specific inactivation...

Whakaahuatanga katoa

I tiakina i:

Ngā taipitopito rārangi puna kōrero
Ngā kaituhi matua:	Aymen Rabai, Léa Reisser, Bernardo Reina-San-Martin, Kamel Mamchaoui, Belinda S. Cowling, Anne-Sophie Nicot, Jocelyn Laporte
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	Elsevier 2019-06-01
Rangatū:	Molecular Therapy: Nucleic Acids
Urunga tuihono:	http://www.sciencedirect.com/science/article/pii/S2162253119300502
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!

Allele-Specific CRISPR/Cas9 Correction of a Heterozygous DNM2 Mutation Rescues Centronuclear Myopathy Cell Phenotypes

Ngā tūemi rite